Desirée Hao - Concepedia

Author

Desirée Hao

University of Calgary ORCID

Also Known As

D HAO, D Hao, D. Hao, Danshi Hao, Desiree Hao, Desirée Hao, Desirée Hao, Desong Hao, Dezhi Hao, Dongxiao Hao

147

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

University of Calgary Alberta Health Services BC Cancer Agency Ottawa Hospital Princess Margaret Cancer Centre

About

Desirée Hao is an author at University of Calgary specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	951
2	Health Sciences	2	2	75
3	Public Health	2	2	78
4	Cell Biology	2	2	74
5	Epidemiology	2	2	78

Desirée Hao

Publications

Citations

H-Index

Page 1

	Year	Citations
Outcome and prognostic factors in soft tissue sarcoma in the adult J. LeVay, Brian O’Sullivan, Charles Catton, International Journal of Radiation OncologyBiologyPhysics Prognostic FactorsSurgical OncologySoft Tissue SarcomaMalignant DiseaseMedicine	1993	204
Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology Roy S. Herbst, Dean F. Bajorin, Harry Bleiberg, Journal of Clinical Oncology Tumor BiologyTargeted Cancer TherapiesMedicineCancer ScreeningCancer Management	2005	120
Sequential treatment with afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: an observational study Maximilian J. Hochmair, Alessandro Morabito, Desirée Hao, Future Oncology	2018	96
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer Barbara Melosky, Helén Anderson, Ronald L. Burkes, Journal of Clinical Oncology	2015	91
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer Janessa Laskin, Garth Nicholas, Christopher Lee, Journal of Thoracic Oncology OncologyMedicineBronchial NeoplasmPlatinum RegimenPhase I/ii Trial	2011	86
Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study Maximilian J. Hochmair, Alessandro Morabito, Desirée Hao, Future Oncology	2019	82
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Annals of Oncology Nivolumab Versus DocetaxelMedicinePharmacologyAnti-cancer AgentPhase Iii Study	2023	78
CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer Shannon Otsuka, Alexander C. Klimowicz, Karen Kopciuk, Journal of Thoracic Oncology Poor OutcomeMedicinePathologyBronchial NeoplasmCancer Biology	2011	71
Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment Desirée Hao, M. Omair Sarfaraz, Farshad Farshidfar, Metabolomics	2016	69
Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study Maximilian J. Hochmair, Alessandro Morabito, Desirée Hao, Future Oncology	2020	69

Page 1